Moneycontrol
HomeNewsBusinessCOVID-19 impact: Infosys to practise 'hybrid' work model to build ‘social capital’
Trending Topics

COVID-19 impact: Infosys to practise 'hybrid' work model to build ‘social capital’

Infosys CEO Salil Parekh said the company had built a flexible model to facilitate work from home.

December 16, 2020 / 11:37 IST
Story continues below Advertisement

Infosys CEO Salil Parekh said on December 15 that the company would prefer a flexible hybrid work model wherein employees would not have to come to the office every day. At a virtual conference, Parekh said the company had built a flexible model to facilitate work from home. It is now time to start working on building ‘social capital’, he said.

Parekh said that - going forward - the company would focus on putting in place a hybrid work model as it would depend on how the situation evolves.

Story continues below Advertisement

"However, the flexibility will remain critical," he said.

There will be flexibility in the models that will allow employee work from different locations at different times, he added.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show